7Baggers

Equillium Quarterly Income Statements Chart

Quarterly
 | 
Annual
 
 Revenue  
 Operating Profit  
 Net Income  
20181231 20191231 20201231 20211231 20221231 20230930 20231231 20240331 20240630 20240930 20241231 20250331 20250630 -6.23-3.36-0.492.385.258.1210.9813.85Milllion

Equillium Quarterly Income Statements Table

Quarterly
 | 
Annual
 
Unit: USD2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31 
               
  revenue 10,689,000 4,392,000 12,161,000 13,853,000 8,879,000 9,211,000 8,870,000      
  yoy 20.39% -52.32% 37.10%          
  qoq 143.37% -63.88% -12.21% 56.02% -3.60% 3.84%       
  operating expenses:             
  research and development4,083,000 9,743,000 7,315,000 9,562,000 10,808,000 9,272,000 9,184,000 8,974,000      
  general and administrative2,145,000 3,737,000 1,775,000 3,278,000 3,145,000 3,715,000 3,227,000 3,519,000      
  total operating expenses6,228,000 13,480,000 9,090,000 12,840,000 13,953,000 12,987,000 12,411,000 12,493,000      
  income from operations-6,228,000 -2,791,000 -4,698,000 -679,000 -100,000 -4,108,000 -3,200,000 -3,623,000      
  yoy6128.00% -32.06% 46.81% -81.26%          
  qoq123.15% -40.59% 591.90% 579.00% -97.57% 28.37% -11.68%       
  operating margin % -26.11% -106.97% -5.58% -0.72% -46.27% -34.74% -40.85%      
  other income, net:             
  interest income122,000 439,000 239,000 331,000 371,000 639,000 517,000 551,000      
  other income367,000 -382,000 -974,000 341,000 197,000 -179,000 357,000 -142,000      
  total other income489,000 57,000 -735,000 672,000 568,000 228,000 874,000 409,000      
  net income-5,739,000 -2,734,000 -5,794,000 -7,000 468,000 -3,940,000 -2,342,000 -3,710,000      
  yoy-1326.28% -30.61% 147.40% -99.81%          
  qoq109.91% -52.81% 82671.43% -101.50% -111.88% 68.23% -36.87%       
  net income margin % -25.58% -131.92% -0.06% 3.38% -44.37% -25.43% -41.83%      
  other comprehensive income, net:             
  unrealized loss on available-for-sale securities -22,000            
  foreign currency translation gain-346,000 305,000 793,000 -275,000 -166,000 133,000 -348,000 99,000      
  total other comprehensive income-346,000 283,000 784,000 -254,000 -172,000 229,000 -318,000 118,000      
  comprehensive loss-6,085,000 -2,451,000 -5,010,000 -261,000  -3,711,000 -2,660,000 -3,592,000      
  net income per share -0.08 -0.17  -0.11 -0.06 -0.11      
  basic-0.16    0.01         
  diluted-0.16    0.01         
  weighted-average number of common shares outstanding:             
  basic35,719,317    35,292,035         
  diluted35,719,317    36,589,774         
  net income per share -0.08 -0.17  -0.11 -0.06 -0.11      
  weighted-average number of common shares outstanding, basic and diluted 35,254,752 35,357,641 35,424,388  34,414,149 34,726,384 34,878,700      
  interest expense     -232,000        
  income before income taxes  -568,250 -7,000 468,000 -3,880,000 -2,607,250 -3,214,000      
  income tax expense     60,000 16,000 496,000      
  unrealized gain on available-for-sale securities  -9,000 21,000 -6,000 96,000 30,000 19,000      
  comprehensive income    296,000         
  acquired in-process research and development             

We provide you with 20 years income statements for Equillium stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Equillium stock. Explore the full financial landscape of Equillium stock with our expertly curated income statements.

The information provided in this report about Equillium stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.